PRESENTATIONS

"Successes and Challenges of CAR T-Cell Therapies for Cancer"

Krishna Komanduri, MD                                                    
Chief, UCSF Division of Hematology and Oncology
Physician-in-Chief, UCSF Helen Diller Family Comprehensive Cancer Center                         
Julius R. Krevans Distinguished Professor of Medicine 

After completing this course, attendees will have improved their skills and strategies for:

• Understanding principles and indications of CAR T-cell therapies for cancer
• Describing approved indications and recognizing immediate and delayed complications of CAR T-cell therapies for cancer
• Recognizing indications for CAR T-cell therapy referral and barriers to therapy, including accessibility and cost

-------

"CAR T-Cell Therapy in Patients With Lymphoma: Present and Future"

C. Babis Andreadis, MD, MSCE
Professor of Medicine
UCSF Division of Hematology and Oncology
Director, UCSF Baszucki Lymphoma Therapeutics Initiative

After completing this course, attendees will have improved their skills and strategies for:

• Appreciating the role of CAR T-cell therapy in patients with relapsed or refractory B-cell lymphomas
• Learning the specific toxicity patterns and outcome measures in lymphoma patients treated with CAR T-cell therapy
• Understanding active areas of research and future developments in the field

-------

"Dawn of a New Era: CAR T-Cell Therapy for Multiple Myeloma"

Sandy W. Wong, MD
Assistant Clinical Professor
UCSF Division of Hematology and Oncology 
Hematology, Blood and Marrow Transplant and Cellular Therapy Program
UCSF Helen Diller Family Comprehensive Cancer Center

After completing this course, attendees will have improved their skills and strategies for:

• Knowing the different CAR T-cell products for relapsed and refractory multiple myeloma
• Describing short-term and long-term CAR T-cell therapy toxicities seen in myeloma patients
• Understanding the future CAR T-cell therapies under development for myeloma patients

-------

"Improving the Success of CAR T-Cells and Applications to Solid Tumors"

Julia Carnevale, MD
Assistant Clinical Professor
UCSF Division of Hematology and Oncology
Gladstone-UCSF Institute of Genomic Immunology

After completing this course, attendees will have improved their skills and strategies for:

• Understanding the unique challenges for CAR T-cells in solid tumors
• Understanding some of the research efforts to circumvent these challenges
• Making sense of the outcomes of some recent CAR T-cell clinical trials in solid tumors

-------

 REGISTRATION

To secure your spot, please register in advance. 

• REGISTER WITH CME
• REGISTER WITHOUT CME